if you scoll down to " Lungenkrebs (NSCLC, Zweitlinintherapie" ( Lung cancer nsclc...written in green!)
than you get:
Google Translation (easier for me ;-) )
Study for patients with non-small cell lung cancer ( NSCLC) in advanced stages with progressive disease after platinum-based chemotherapy or with known EGFR mutation by a tyrosine kinase inhibitor therapy directed at EGFR.
Drug trial (Phase III) with docetaxel plus Bavituximab versus docetaxel plus placebo